Recent Updates
Recently added Catalysts

Interferon beta-1a

Phase 2

Multiple Sclerosis, Relapsing-Remitting | Monoclonal antibody | Immunology |Sanofi|Last Updated: Jan 8, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment334
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00050778A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisPHASE2 COMPLETED 334Dec 1, 2002Jan 1, 2010Jan 8, 201549 United States, Croatia +3
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Probability of Participants With Sustained Accumulation of Disability (SAD)
Up to 3 years

EDSS is an ordinal scale in half-point increments that quantifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with Baseline score of 1.0 or more; and the increase persisted for at least next the 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Probability of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.

Annualized Relapse Rate
Up to 3 years

Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated using a Poisson regression model with observed number of relapses as a dependent variable, the log total amount of follow-up from date of randomization for each participant as an offset variable and treatment group indicator as a covariate.

Secondary Endpoints
Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment
Year 3
Percent Change From Baseline in T1 Cerebral Volume at Year 3
Baseline, Year 3
Percent Change From Baseline in MRI T2 Lesion Volume at Year 3
Baseline, Year 3
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Interferon Beta-1aACTIVE_COMPARATOR -
Alemtuzumab 12 mgEXPERIMENTAL -
Alemtuzumab 24 mgEXPERIMENTAL -
Interventions
NameTypeDescription
Interferon beta-1aBIOLOGICALInterferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
Alemtuzumab 12 mgBIOLOGICALAlemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).
Alemtuzumab 24 mgBIOLOGICALAlemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersNo
Study Sites49

Inclusion Criteria: * Signed informed consent form (ICF) * Male or non-pregnant, non-lactating female participants, 18 to 50 years of age (inclusive) as of signing the ICF * Diagnosis of MS per McDonald's update of the Poser criteria, including cranial MRI consistent with those criteria (McDonald, ...

Countries:United StatesCroatiaPolandRussiaUnited Kingdom
Unlock Eligibility Criteria